Skip to main content

Advertisement

Table 1 Clinicopathological characteristics of patients with triple-negative breast cancer (TNBC) with respect to autophagy-related gene 5 (ATG5) rs473543 genotypes

From: Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy

Characteristic Total [cases (%)] ATG5 rs473543 genotype [cases (%)] P
AA GG GA
Total 316 60 112 144  
Age (years) 0.233
 ≤ 40 74 (23.4) 11 (18.3) 23 (20.5) 40 (27.8)  
 > 40 242 (76.6) 49 (81.7) 89 (79.5) 104 (72.2)  
T stage 0.231
 pT0–T1 156 (49.4) 35 (58.3) 50 (44.6) 71 (49.3)  
 pT2–T4 160 (50.6) 25 (41.7) 62 (55.4) 73 (50.7)  
Axillary lymph node status 0.543
 Negative 199 (63.0) 41 (68.3) 67 (59.8) 91 (63.2)  
 Positive 117 (37.0) 19 (31.7) 45 (40.2) 53 (36.8)  
TNM stage 0.948
 0–I 109 (34.5) 20 (33.3) 38 (33.9) 51 (35.4)  
 II–III 207 (65.5) 40 (66.7) 74 (66.1) 93 (64.6)  
Pathological type 0.855
 Invasive ductal carcinoma 294 (93.0) 58 (96.7) 102 (91.1) 134 (93.1)  
  Grade 1/2 109 (34.5) 24 (40.0) 37 (33.0) 48 (33.3)  
  Grade 3 164 (51.9) 30 (50.0) 57 (50.9) 77 (53.5)  
  Unknown 21 (6.6) 4 (6.7) 8 (7.1) 9 (6.3)  
 Others 22 (7.0) 2 (3.3) 10 (8.9) 10 (6.9)  
Vascular invasion 0.594
 Yes 46 (14.6) 7 (11.7) 15 (13.4) 24 (16.7)  
 No 270 (85.4) 53 (88.3) 97 (86.6) 120 (83.3)  
Adjuvant radiotherapy 0.396
 Yes 121 (38.3) 21 (35.0) 39 (34.8) 61 (42.4)  
 No 195 (61.7) 39 (65.0) 73 (65.2) 83 (57.6)  
Chemotherapeutic regimensa 0.455
 Anthracycline-based 222 (70.3) 43 (71.7) 67 (59.8) 112 (77.8)  
 Taxane-based 251 (79.4) 47 (78.3) 95 (84.8) 109 (75.7)  
 Anthracycline-taxane combination 157 (70.7) 30 (50.0) 50 (44.6) 77 (53.5)  
  1. aPatients who received anthracyclines as chemotherapeutic treatment may also receive taxanes as chemotherapy at the same time. Double counting resulted in the sum higher than the number of subjects investigated in this study